Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANNIVERSARY observational study of adjuvant nivolumab for muscle-invasive urothelial carcinoma in Japan
jRCT1031230091Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in transitional cell carcinoma (TCC), bladder cancer and upper tract urothelial carcinoma (UTUC), sponsored by Bristol Myers Squibb. Primary endpoints: Disease-free survival, Non-urothelial tract recurrence-free survival and 3 more. Started Jul 2023; status: active, not recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)bladder cancerupper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on jRCT1031230091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230091.